RC
SCLN

RegentAtlantic Capital’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

RegentAtlantic Capital’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-300
Closed -$2.63K – 1117
2014
Q4 		$2.63K Buy
+300
New +$2.43K ﹤0.01% 1100

Other funds holding SCLN

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
SI
Sensato Investors San Francisco, California $122M AUM 5.69% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

RegentAtlantic Capital's SCLN Position: Q1 2015 in Review

RegentAtlantic Capital sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q1 2015, closing a stake of 300 shares — an estimated $2.63K sold.

RegentAtlantic Capital first reported a position in SCLN in Q4 2014 and held it in 1 quarter. The position peaked at $2.63K in Q4 2014. 130 funds tracked by Wall St. Rank hold SCLN as of Q1 2015.

  • RegentAtlantic Capital reported no remaining Sciclone Pharmaceuticals Inc position as of Q1 2015 after selling out during the quarter.
  • RegentAtlantic Capital sold 300 Sciclone Pharmaceuticals Inc shares in Q1 2015, an estimated $2.63K.
  • RegentAtlantic Capital first reported a position in Sciclone Pharmaceuticals Inc in Q4 2014 and held it in 1 quarter.
  • RegentAtlantic Capital's Sciclone Pharmaceuticals Inc position peaked at $2.63K in Q4 2014.
  • 130 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q1 2015.

Based on RegentAtlantic Capital's 13F filing for Q1 2015, filed 27 Apr 2015.